ID

32585

Beschreibung

Pilot Study of the Treatment of Vascular Endothelial Growth Factor(VEGF)Signaling Pathway Inhibitor-Induced Hypertension; ODM derived from: https://clinicaltrials.gov/show/NCT00607477

Link

https://clinicaltrials.gov/show/NCT00607477

Stichworte

Versionen (1)
  1. 07.11.18 07.11.18 -
Rechteinhaber

See clinicaltrials.gov

Hochgeladen am

7. November 2018

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY 4.0
Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Zurück zu Modell Kommentaren
Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility Treatment Induced Hypertension NCT00607477

Englisch

Eligibility Treatment Induced Hypertension NCT00607477

1 Formulare  
Inclusion Criteria
Beschreibung

Inclusion Criteria

Alias
UMLS CUI
C1512693
ongoing treatment for malignancy by at the university of chicago with any agent with recognized, specific inhibition of vegf, vegf-receptors, or downstream signaling molecules with the specific intention of inhibiting signaling of this pathway. these agents include but are not limited to: bevacizumab (avastin™), sorafenib (nexavar™), sunitinib (sutent™), axitinib (ag-013736), and azd 2171.
Beschreibung

Cancer treatment | Vascular Endothelial Growth Factor Inhibitors | Vascular Endothelial Growth Factor Receptor inhibitors | bevacizumab | Avastin | sorafenib | Nexavar | sunitinib | Sutent | axitinib | AG 013736 | AZD2171

Datentyp

boolean

Alias
UMLS CUI [1]
C0920425
UMLS CUI [2]
C4522891
UMLS CUI [3,1]
C0148199
UMLS CUI [3,2]
C0243077
UMLS CUI [4]
C0796392
UMLS CUI [5]
C1135130
UMLS CUI [6]
C1516119
UMLS CUI [7]
C1677799
UMLS CUI [8]
C1176020
UMLS CUI [9]
C1698963
UMLS CUI [10]
C1700874
UMLS CUI [11]
C1328149
UMLS CUI [12]
C1541530
treatment of hypertension with at least 2 or more anti-hypertensive medications with blood pressure remaining greater than 140/90 mmhg.
Beschreibung

Antihypertensive therapy | Antihypertensive Agents Quantity | Blood pressure determination

Datentyp

boolean

Alias
UMLS CUI [1]
C0585941
UMLS CUI [2,1]
C0003364
UMLS CUI [2,2]
C1265611
UMLS CUI [3]
C0005824
stable management of other toxicities from the cancer treatments
Beschreibung

Toxicity Due to Cancer treatment | Management Stable

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0600688
UMLS CUI [1,2]
C0678226
UMLS CUI [1,3]
C0920425
UMLS CUI [2,1]
C0376636
UMLS CUI [2,2]
C0205360
expected to continue current cancer treatments for at least 4 weeks
Beschreibung

Cancer treatment Duration Expected

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0920425
UMLS CUI [1,2]
C0449238
UMLS CUI [1,3]
C1517001
18 years and older
Beschreibung

Age

Datentyp

boolean

Alias
UMLS CUI [1]
C0001779
ability to understand and the willingness to sign a written informed consent document prior to any study specific procedures.
Beschreibung

Informed Consent

Datentyp

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Beschreibung

Exclusion Criteria

Alias
UMLS CUI
C0680251
concurrent use of hematopoietic supportive treatment with erythropoietin or congeners.
Beschreibung

Erythropoietin | Erythropoietin congener

Datentyp

boolean

Alias
UMLS CUI [1]
C0014822
UMLS CUI [2,1]
C0014822
UMLS CUI [2,2]
C0678518
current uncontrolled toxicities due to the cancer treatments.
Beschreibung

Toxicity Uncontrolled | Toxicity Due to Cancer treatment

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0600688
UMLS CUI [1,2]
C0205318
UMLS CUI [2,1]
C0600688
UMLS CUI [2,2]
C0678226
UMLS CUI [2,3]
C0920425
patients having known contraindications to hydralazine or minoxidil therapy.
Beschreibung

Medical contraindication Hydralazine | Medical contraindication Minoxidil

Datentyp

boolean

Alias
UMLS CUI [1,1]
C1301624
UMLS CUI [1,2]
C0020223
UMLS CUI [2,1]
C1301624
UMLS CUI [2,2]
C0026196
any readings of systolic blood pressure >200 mmhg or diastolic blood pressure >120 mmhg in the four (4) weeks prior to screening.
Beschreibung

Systolic Pressure | Diastolic blood pressure

Datentyp

boolean

Alias
UMLS CUI [1]
C0871470
UMLS CUI [2]
C0428883
use of either minoxidil or hydralazine in the six (6) months prior to screening.
Beschreibung

Minoxidil | Hydralazine

Datentyp

boolean

Alias
UMLS CUI [1]
C0026196
UMLS CUI [2]
C0020223
Zum Seitenanfang zurückkehren

Ähnliche Modelle

Eligibility Treatment Induced Hypertension NCT00607477

1 Formulare
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
C1512693 (UMLS CUI)
Cancer treatment | Vascular Endothelial Growth Factor Inhibitors | Vascular Endothelial Growth Factor Receptor inhibitors | bevacizumab | Avastin | sorafenib | Nexavar | sunitinib | Sutent | axitinib | AG 013736 | AZD2171
Item
ongoing treatment for malignancy by at the university of chicago with any agent with recognized, specific inhibition of vegf, vegf-receptors, or downstream signaling molecules with the specific intention of inhibiting signaling of this pathway. these agents include but are not limited to: bevacizumab (avastin™), sorafenib (nexavar™), sunitinib (sutent™), axitinib (ag-013736), and azd 2171.
boolean
C0920425 (UMLS CUI [1])
C4522891 (UMLS CUI [2])
C0148199 (UMLS CUI [3,1])
C0243077 (UMLS CUI [3,2])
C0796392 (UMLS CUI [4])
C1135130 (UMLS CUI [5])
C1516119 (UMLS CUI [6])
C1677799 (UMLS CUI [7])
C1176020 (UMLS CUI [8])
C1698963 (UMLS CUI [9])
C1700874 (UMLS CUI [10])
C1328149 (UMLS CUI [11])
C1541530 (UMLS CUI [12])
Antihypertensive therapy | Antihypertensive Agents Quantity | Blood pressure determination
Item
treatment of hypertension with at least 2 or more anti-hypertensive medications with blood pressure remaining greater than 140/90 mmhg.
boolean
C0585941 (UMLS CUI [1])
C0003364 (UMLS CUI [2,1])
C1265611 (UMLS CUI [2,2])
C0005824 (UMLS CUI [3])
Toxicity Due to Cancer treatment | Management Stable
Item
stable management of other toxicities from the cancer treatments
boolean
C0600688 (UMLS CUI [1,1])
C0678226 (UMLS CUI [1,2])
C0920425 (UMLS CUI [1,3])
C0376636 (UMLS CUI [2,1])
C0205360 (UMLS CUI [2,2])
Cancer treatment Duration Expected
Item
expected to continue current cancer treatments for at least 4 weeks
boolean
C0920425 (UMLS CUI [1,1])
C0449238 (UMLS CUI [1,2])
C1517001 (UMLS CUI [1,3])
Age
Item
18 years and older
boolean
C0001779 (UMLS CUI [1])
Informed Consent
Item
ability to understand and the willingness to sign a written informed consent document prior to any study specific procedures.
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Erythropoietin | Erythropoietin congener
Item
concurrent use of hematopoietic supportive treatment with erythropoietin or congeners.
boolean
C0014822 (UMLS CUI [1])
C0014822 (UMLS CUI [2,1])
C0678518 (UMLS CUI [2,2])
Toxicity Uncontrolled | Toxicity Due to Cancer treatment
Item
current uncontrolled toxicities due to the cancer treatments.
boolean
C0600688 (UMLS CUI [1,1])
C0205318 (UMLS CUI [1,2])
C0600688 (UMLS CUI [2,1])
C0678226 (UMLS CUI [2,2])
C0920425 (UMLS CUI [2,3])
Medical contraindication Hydralazine | Medical contraindication Minoxidil
Item
patients having known contraindications to hydralazine or minoxidil therapy.
boolean
C1301624 (UMLS CUI [1,1])
C0020223 (UMLS CUI [1,2])
C1301624 (UMLS CUI [2,1])
C0026196 (UMLS CUI [2,2])
Systolic Pressure | Diastolic blood pressure
Item
any readings of systolic blood pressure >200 mmhg or diastolic blood pressure >120 mmhg in the four (4) weeks prior to screening.
boolean
C0871470 (UMLS CUI [1])
C0428883 (UMLS CUI [2])
Minoxidil | Hydralazine
Item
use of either minoxidil or hydralazine in the six (6) months prior to screening.
boolean
C0026196 (UMLS CUI [1])
C0020223 (UMLS CUI [2])
Zum Seitenanfang zurückkehren 

Kontakt

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video